4D Molecular Therapeutics Inc.

Genetic medicines company $FDMT, is crossing above the intraday high it reached when it gapped up in early February on reported results from a mid-stage trial of its eye disease therapy.

Share This Article

 

About the Author

4D Molecular Therapeutics Inc.

Joey Ramson